InnovAge Holding Corp. Q4 2026 Earnings Call Summary

Strategic Transition to Platform Optimization

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Management characterized fiscal 2026 as the completion of 'InnovAge 2.0,' transitioning from a period of regulatory remediation to a durable, disciplined operating model.

Performance attribution for the year was driven by improved medical cost management, better-than-expected rate environments, and the successful insourcing of pharmacy services.

The 'InnovAge 3.0' framework prioritizes scaling the existing footprint while exploring de novo markets, M&A, and joint ventures to expand reach.

Operational context highlights a shift toward 'payer-provider' capabilities, utilizing data from Epic and Salesforce to drive proactive clinical interventions.

Strategic positioning focuses on the interdisciplinary care team (IDT) as the core engine for managing the total cost of care for medically complex seniors.

Management emphasized that quality and compliance remain 'non-negotiable' foundations as the company pursues more aggressive growth targets.

Fiscal 2027 Outlook and Efficiency Initiatives

Guidance for fiscal 2027 assumes a 'tempered' rate environment compared to 2026, with net Medicare rate increases projected at 1.5% to 2.0%.

Revenue projections of $1.05B to $1.085B incorporate responsible assumptions for California and Colorado rates, which represent 70% of total census and are not yet finalized.

Strategic initiatives include scaling AI pilots for clinical decision support and medication optimization to reduce external specialist referrals and improve outcomes.

Management expects margin expansion to be driven by execution in enrollment growth and utilization management rather than relying on outsized rate increases.

Future capital allocation will prioritize M&A over de novos if acquisitions offer a superior return on invested capital, citing a 'high bar' for new center builds.

Impact of V28 risk adjustment model on Medicare rates

Management noted that while V28 is a headwind for many, InnovAge sees a partial offset due to high dementia prevalence among participants, which is treated favorably.

The 1.5% to 2.0% net increase projection accounts for the 50-50 phase-in of the new model starting in January.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

M&A strategy versus de novo center development

Management expressed a preference for M&A, specifically targeting underperforming PACE programs that can be integrated into their established platform.

The company is proactively reviewing market opportunities, supported by strong cash flow and a strengthened balance sheet.